To: Board of Supervisors
From: Dr. Grant Colfax, Health Services Director
Report Title: Purchase Order with Vapotherm, Inc.
☒Recommendation of the County Administrator ☐ Recommendation of Board Committee
RECOMMENDATIONS:
APPROVE and AUTHORIZE the Purchasing Agent, or designee, to execute on behalf of the Health Services Director, a one-time purchase order with Vapotherm, Inc. in an amount not to exceed $73,118 and a Service Plan Agreement for the purchase of High Velocity Therapy System 2.0 (HVT), and maintenance and repair services, effective upon signature and for three years thereafter for Contra Costa Regional Medical Center (CCRMC).
FISCAL IMPACT:
Approval of this action will result in a one-time expenditure of up to $73,118 and will be funded by Hospital Enterprise Fund I revenues.
BACKGROUND:
High Velocity Therapy System 2.0 is a respiratory support system developed by Vapotherm, Inc. that provides non-invasive ventilatory support using high-velocity nasal insufflation (HVNI) technology. This system delivers heated, humidified oxygen and air through a simple nasal cannula, offering a comfortable and effective alternative to traditional mask-based ventilation. One of its key features is its integrated air source, which eliminates the need for a wall air supply, making it portable and versatile for various clinical settings. The adjustable oxygen and flow settings allow precise control of oxygen concentration, ranging from 21% to 100%, and flow rates between 5 and 45 liters per minute measured under Body Temperature and Pressure, Saturated (BTPS) conditions, ensuring tailored treatment for each patient. Additionally, the rapid setup enables healthcare providers to initiate therapy within minutes, ensuring timely intervention for patients experiencing respiratory distress.
The current high-flow nasal cannula devices in use at CCRMC have reached the end of their lifecycle and require replacement. Given the critical role these devices play in providing life-saving respiratory support, particularly in intensive care settings, prompt replacement is essential. Acquiring updated units is necessary to ensure the continued delivery of safe, effective, and high-quality patient care.
This purchase is governed by Vapotherm’s VapoCare Service Plan Agreement. Under this agreement, neither party shall be held liable for any special, consequential, incidental, indirect, punitive, or exemplary damages, including lost profits or costs related to procurement. Approval of this request will allow Vapotherm to proceed with the provision of upgraded high-flow nasal cannula units and ensure uninterrupted respiratory support for critical care patients at CCRMC. This purchase is being justified via sole source.
CONSEQUENCE OF NEGATIVE ACTION:
If this action is not approved, CCRMC may face significant challenges in delivering critical respiratory support, potentially compromising patient safety and quality of care.